Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide)
A total of 9 abstracts presented at the 18th Annual European Neuroendocrine Tumor Society (ENETS)…